CriticalTricyclic antidepressants (TCA)×Reversible MAO-A inhibitor (RIMA)
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amitriptyline blocks the reuptake of noradrenaline and serotonin at nerve endings, and together with MAO inhibitors it can cause serotonin syndrome (amitriptyline SmPC, AEMPS). Moclobemide also inhibits the enzyme CYP2C19, so plasma levels of drugs metabolised by this enzyme may rise (moclobemide SmPC, AEMPS). CYP2D6 and CYP2C19 are the main enzymes of amitriptyline metabolism (amitriptyline SmPC, AEMPS). The half-life of moclobemide is about 3 hours (moclobemide SmPC, AEMPS), and that of amitriptyline is about 25 hours (amitriptyline SmPC, AEMPS).
Symptoms
Serotonin syndrome with amitriptyline and monoamine oxidase inhibitors (MAOIs) may include agitation, confusion, tremor, muscle jerks (myoclonus) and hyperthermia (amitriptyline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hyperpyretic crises, severe convulsions and deaths have occurred in patients who took tricyclic antidepressants and MAOIs at the same time (amitriptyline label, US Food and Drug Administration, FDA). Serotonin syndrome may also include hallucinations, delirium and coma, fast heart rate, labile blood pressure, sweating, hyperreflexia, incoordination, seizures, nausea, vomiting and diarrhoea (FDA amitriptyline label). Isolated severe cases with hyperthermia, confusion, hyperreflexia and myoclonus have occurred when moclobemide was combined with other antidepressants (moclobemide SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish amitriptyline summary of product characteristics (SmPC) rules out concomitant monoamine oxidase inhibitors (MAOIs) and names moclobemide among them (amitriptyline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The amitriptyline label of the US Food and Drug Administration (FDA) also says amitriptyline should not be given with MAOIs (FDA amitriptyline label). The moclobemide SmPC is softer: it asks for caution with other antidepressants and allows a tricyclic antidepressant to start the day after moclobemide is stopped (moclobemide SmPC, AEMPS). When switching from moclobemide to amitriptyline, give the first amitriptyline dose at least one day after stopping moclobemide (amitriptyline SmPC, AEMPS). The US label asks for at least 14 days after any MAOI, followed by a cautious start of amitriptyline with gradual dose increases (FDA amitriptyline label). When switching the other way, start moclobemide no earlier than 14 days after stopping amitriptyline (amitriptyline SmPC, AEMPS). If signs of serotonin syndrome appear, stop amitriptyline and other serotonergic drugs at once and start supportive symptomatic treatment (FDA amitriptyline label). Keep the patient under medical observation, in hospital if needed (moclobemide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Amitriptyline hydrochloride tablets (amitriptyline) prescribing information (2026)– FDA label, Sun Pharmaceutical Industries, DailyMed setid 4e520c63-1cf6-40f6-a51c-3f9b0e181342, revised 09/2026, Contraindications, Warnings (Serotonin Syndrome) and PRECAUTIONS: Drug Interactions (Drugs Metabolized by P450 2D6)
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg (nº registro 37130), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg comprimidos recubiertos con película (nº registro 37130), secciones 4.3, 4.4, 4.5 y 4.8 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.3, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2